2912 results about "Immunotherapy" patented technology

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

The invention discloses an intestinal cancer immune response graph neural network prediction method, a medium and equipment, and the method comprises the steps: collecting pathological image information, immunodetection information and basic clinical information, extracting a tissue space distribution characteristic spectrum through a deep convolutional network, and constructing a graph neural network model in combination with an immunomarker expression characteristic matrix; spatial interaction characteristics of a tumor microenvironment are modeled by adopting a graph attention mechanism, finally a treatment response probability, an optimal treatment opportunity and an adverse reaction risk are predicted through a multi-task learning framework, and a clinical decision report containing a prediction response curve, a risk early warning threshold and a treatment time window suggestion is output. According to the method, through multi-modal data fusion and spatial interaction modeling, accurate prediction of intestinal cancer immunotherapy response is realized, and a more comprehensive reference basis is provided for clinical decision making.

Methods for treating tissue with irreversible electroporation and immunotherapy are described. The methods include placing a probe in tissue within a human body, wherein the probe has at least a first electrode, applying a plurality of electrical pulses through the first electrode and a second electrode, causing irreversible electroporation (IRE) of the tissue within a target ablation zone, and administering one or more exogenous agents into the tissue within the target ablation zone or to the human, thereby stimulating or otherwise modulating an immune system response within the body.

The invention discloses a renal clear cell carcinoma prognosis prediction method based on multi-mode MRI (Magnetic Resonance Imaging) image and digital pathological omics fusion. The method comprises the following steps: S1, collecting a training data set based on an MR image and a pathological image; s2, feature extraction of MR radiomics; s3, deep learning feature extraction of the pathological image; s4, an MR-pathological feature fusion module; and S5, deploying the network. According to the method, depth features with prognosis information are obtained from two scales of pre-treatment images and post-operation pathology, effective features are extracted by adopting image omics and a convolutional neural network mode according to data characteristics of MR images and pathology images, and depth fusion of the two types of features is completed in a hidden space through a multi-task guiding mode, so that the accuracy of the MR image and the pathology image is improved. A precise prognosis model with multi-scale information is provided, and the method has a relatively strong clinical application prospect and is of great significance for realizing precise immunotherapy and improving prognosis of a patient.

Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. A balance of precision and recall can be applied to at least one of a toxicity-related model or an efficacy-related model to configure immunotherapy treatment of a patient and / or cohort of patients. Model output can be evaluated differently depending on a determine patient selection criterion to trigger different actions.

The invention discloses preparation of a targeting LYPD3 antibody and application of the targeting LYPD3 antibody in tumor immunotherapy. The antibody or antigen binding fragment thereof comprises a heavy chain variable region having CDR-H1, CDR-H2 and CDR-H3 and a light chain variable region having CDR-L1, CDR-L2 and CDR-L3 wherein CDR-H1, CDR-H2 and CDR-H3 comprise the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and CDR-L1, CDR-L2 and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

The invention provides a tumor immunotherapy curative effect prediction system based on polarization characteristics of neutrophil, and relates to the technical field of biology, the system comprises a neutrophil detection module used for determining neutrophil information; the patient information module is used for acquiring tumor information and immune information of a patient; the immunotherapy scheme information module is used for acquiring immunotherapy scheme information of the patient; the historical data acquisition module is used for acquiring historical patient information; the immune state coefficient module is used for determining the immune state coefficient of the patient; the prediction model module is used for obtaining the predicted tumor size through the trained tumor size prediction model; the immune state prediction module is used for determining a predicted immune state coefficient; and the curative effect prediction module is used for determining a predicted tumor immunotherapy curative effect score. According to the invention, the predicted tumor immunotherapy curative effect can be evaluated according to two aspects of predicting the tumor size and predicting the immune state coefficient.

The invention relates to the technical field of biology, in particular to a preparation method and application of an anti-human MUC1 antibody, and provides a recombination system which utilizes an in-vitro B cell culture technology, uses ELISA (enzyme-linked immunosorbent assay) to detect the expression condition of the antibody, performs flow detection on the binding capacity level with cells and performs antibody expression and assembly through an expression vector. The monoclonal antibody with high specificity and strong affinity is screened out, and the immunogenicity is reduced on the basis that the high affinity combined with the antigen is reserved through humanized transformation, so that the monoclonal antibody is favorably applied to immunotherapy of a human body; the anti-human MUC1 antibody prepared by the invention plays an important role in immunotherapy of tumors, and solves the technical problems of insufficient specificity and lower affinity of the MUC1 antibody in the prior art.

Presented herein are systems, methods, and non-transient computer readable media for determining predicted response scores of subjects. A computing system may identify a first feature set for a first subject to be administered with immunotherapy to address a condition. The first feature set may include one or more of: (i) a first radiological feature identified in a tomogram of a section associated with the condition in the first subject, (ii) a first immunohistochemistry (IHC) feature derived from an image of a sample associated with the first subject, and (iii) a first genomic feature obtained from gene sequencing of the first subject for genes associated with the condition. The computing system may apply the first feature set to a model. The computing system may determine, from applying the first feature set to the model, a predicted score identifying a response to the immunotherapy to be administered to the first subject.

The invention discloses a bispecific cytokine fusion protein, which comprises an amino acid sequence of a type I cytokine and an amino acid sequence of a type II cytokine, and the amino acid sequence of the type I cytokine and the amino acid sequence of the type II cytokine are directly connected through a connecting peptide or are connected in series or in parallel through a fusion partner and the connecting peptide. Amino acid sequences of type I and type II cytokines are connected in series or in parallel to form the bispecific cytokine fusion protein, and the fusion protein can synergistically activate precursor depleted CD8 + T cells and terminal depleted CD8 + T cells, improve immunosuppression of a solid tumor complex microenvironment and release the potential of tumor immunotherapy. The invention further discloses nucleic acid, a carrier, a cell, a medicine or a medicine composition related to the bispecific cytokine fusion protein. The invention also discloses application of the bispecific cytokine fusion protein in preparation of drugs for treating cancers.

The invention belongs to the technical field of medicines, and discloses parthenolide derivatives (general formula I), pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof and an application thereof, especially an application of the parthenolide derivatives in preparation of anti-tumor and immunotherapy medicines. # imgabs0 #

The invention discloses an esophageal cancer neoadjuvant chemotherapy and post-immunization pathology complete remission prediction system and method, and relates to the field of medical image processing, and the system comprises an image processing module which is used for carrying out the standardized processing of an input image, and segmenting a tumor region in the image; the feature extraction module is used for extracting voxel-level radiomics features from the tumor area; the feature screening module is used for screening out a plurality of voxel-level radiomics features with the most predictive capability; and the pathology prediction module is used for generating a comprehensive feature vector according to the segmented input image and the screened voxel-level radiomics features, and predicting the curative effect of the combination of neoadjuvant chemotherapy and immunotherapy according to the comprehensive feature vector. According to the technical scheme provided by the invention, the accuracy of predicting complete pathologic remission after neoadjuvant chemotherapy and immunotherapy of esophageal cancer can be improved, the defect that the heterogeneity in tumors cannot be considered in a traditional imaging omics technology is overcome, and the method has a relatively high application value.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a cascade response type nano-particle with a microenvironment remodeling function and a preparation method and application of the cascade response type nano-particle. The nanoparticle provided by the invention adopts a bionic hybrid membrane engineering strategy: an inner core is formed by loading an exosome inhibitor on a nano material, and the surface is covalently coupled with M2 type macrophage specific targeting peptide; the outer layer coats a macrophage membrane and active oxygen response type liposome composite membrane layer through a co-extrusion technology, and is loaded with a TLR agonist. Animal experiments show that after being injected through caudal vein, the nano-particles are enriched at a tumor site in a targeted manner through homing receptors such as membrane surface integrin alpha4beta1 and the like, and outer membrane cracking is triggered in a high-ROS tumor microenvironment, so that space-time controlled release of a TLR agonist and targeted phagocytosis of an exosome inhibitor by macrophages guided by a targeted peptide are realized. The anti-tumor synergistic effect is achieved through multiple regulation and control mechanisms, and an effective treatment strategy is provided for tumor immunotherapy.

The invention belongs to the cross technical field of nanomedicine, tumor treatment and immunotherapy, and particularly provides tumor mitochondria-targeted copper death selective induction nanoparticles, which are prepared by the following preparation method: S1, specifically coupling TPY and MHI through condensation reaction to obtain MTPY; s2, MTPY and copper ions are subjected to complexation, and an MTPY-Cu complex is obtained; and S3, the MTPY-Cu complex and albumin are subjected to self-assembly, and the MTPY-Cu-coated Alb nanoparticles are formed. The dosage of copper is only 1 / 1000 of that of free Cu < 2 + >, and equivalent immune regulation and killing effects can be achieved; primary tumors and distant tumor focuses can be inhibited, and lung metastasis is reduced; immune memory can be induced, and relapse can be prevented; the traditional Chinese medicine composition is combined with cis-platinum to remarkably enhance the curative effect and reverse the induced immunosuppression; the invention has the advantages of high biological safety and no obvious liver and kidney toxicity or hemolytic reaction.

The invention relates to an immune humanized liver cancer patient-sourced xenotransplantation mouse model and a construction method and application thereof, and belongs to the technical field of medical research and biologication.The immune humanized liver cancer PDX model is innovatively constructed by optimizing transplantation of tumor tissues and introducing and screening immune cells, and the model has the advantages of being high in specificity, high in sensitivity and high in reliability. The defects of a traditional PDX model in immune system and immunotherapy evaluation are overcome. The model has tumor characteristics of liver cancer patients and a functional human immune system, has reliable immune response and anti-cancer treatment evaluation capability, and provides scientific and reliable model support for research and screening of novel liver cancer immunotherapy.

Described herein are methods and systems of performing immunotherapy on a subject and / or determining if a subject will be responsive to ablation immunotherapy.

The invention belongs to the field of biological catalytic materials, particularly relates to a sound-sensitive agent based on a metal-pyridine coordination structure as well as a preparation method and application of the sound-sensitive agent, and more particularly relates to a sound-sensitive agent doped with second metal and based on the metal-pyridine coordination structure. Compared with other most reported sound-sensitive agents based on micromolecules, the sound-sensitive agent based on the metal-pyridine coordination structure and the doped second metal and based on the metal-pyridine coordination structure, especially the latter, has higher ultrasonic mediated < 1 > O2 generation activity; in addition, the effects of relieving oxygen deficit, promoting polarization of macrophages to M1 and enhancing immunotherapy are achieved, and therefore the tumor microenvironment of immunosuppression is reversed. When the sonosensitizer provided by the invention is used in combination with a PD-L1 antibody, satisfactory sonodynamic triggered synchronous immune activation is realized, and original and distant metastatic tumors are eradicated impressively.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention relates to a biomarker for predicting the curative effect of non-small cell lung cancer immunotherapy and application of the biomarker. The biomarker for predicting the curative effect of the non-small cell lung cancer immunotherapy, disclosed by the invention, comprises phosphoglycerate kinase 1 (PGK1), chromogranin A (CHGA), elastin (ELN), heterogeneous ribonucleoprotein H3 (HNRNPH3) and SERPINE1 mRNA binding protein 1 (SERBP1). The biomarkers for predicting the non-small cell lung cancer immunotherapy curative effect can be detected by adopting a mass spectrum method, and the non-small cell lung cancer immunotherapy curative effect of a patient is judged by the markers.

The invention discloses a new medicine application of a local injection acoustic response stent in enhancing ultrasound histotripsy. The acoustic response scaffold (ARS) comprises a scaffold material, fluorocarbon gas or liquid fluorocarbon particles with liquid-vapor phase change capacity, and microbubble cloud in the scaffold generates a strong cavitation ablation treatment effect in a target area under the action of low-frequency and low-sound-pressure ultrasound. Fluorocarbon gas or liquid fluorocarbon particles contained in the ARS form microbubble cloud and ideal cavitation nuclei under low-frequency low-sound-pressure ultrasonic excitation, inertia cavitation resonance is achieved under the ultrasonic action, and then cavitation mechanical damage with local tissue controllable strength is generated. The low-intensity ultrasonic histotripsy has the characteristics of low sound pressure, low sound intensity, high targeting property, small tissue damage outside a target region, simplicity in instrument manufacturing and the like, and the targeting property and the safety of treatment are improved. The method does not need very accurate ultrasonic focusing, reduces the operation difficulty, and has application prospects in multiple medical fields such as prostatic hyperplasia, tumor ablation and tumor immunotherapy.

The invention provides a coordination nano assembly of chiral cyclopeptide and manganese ions as well as a preparation method and application of the coordination nano assembly. According to the method, a manganese superoxide dismutase protein structural domain and a unique tumor microenvironment of melanoma high tyrosinase are combined, and polypeptide sequences L-YD-hL-DD-h, L-YL-HL-DL-H and D-yD-hD-dD-h with different chirality are designed for the first time; the chirality of the polypeptide is regulated and controlled, the in-vivo circulation stability and the cell entry efficiency of the nano assembly are improved, the coordination self-assembly of manganese and different chiral cyclopeptides is realized, and the in-situ oxidation of an in-vivo tumor microenvironment is simulated for photo-thermal therapy and cell membrane coating. The method disclosed by the invention is simple, mild in experimental condition and easy to operate, the prepared cell membrane coated nano assembly not only has long circulation stability and high cell entry efficiency, but also can realize mild photo-thermal therapy through in-situ oxidation, releases manganese ions to activate a CGAS-STING pathway for immunotherapy of tumors, and has a wide application prospect. The potential application value is realized in the field of combined treatment of tumors.

The invention provides an AS01 derivative adjuvant, a preparation method thereof and application of the AS01 derivative adjuvant in preparation of vaccines or anti-tumor drugs, and belongs to the technical field of biological drugs or products. The AS01 derivative adjuvant is prepared from the following components in parts by mass: 0.5 to 1.0 part of cholesterol, 2.0 to 4.0 parts of dioleoyl lecithin and at least one of the following components in parts by mass: 0.1 to 0.2 part of monophosphoryl lipid A, 0.1 to 0.2 part of QS-21, 0.36 to 0.72 part of 3M-052, 0.4 to 0.8 part of muramyl dipeptide and 0.2 to 0.4 part of oligodeoxynucleotide. According to the AS01 derived adjuvant, a novel synergistic adjuvant system is developed by integrating various immunomodulators, so that the immunogenicity of a vaccine is enhanced. The HPV vaccine is prepared on the basis of the AS01 derived adjuvant, so that the immunogenicity can be enhanced, and good anti-tumor activity can be achieved. Therefore, the invention provides a new strategy for immunotherapy of HPV-related tumors.

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

The invention discloses a tumor immunotherapy curative effect prediction method and system based on multi-modal data, and the method comprises the steps: firstly, obtaining the multi-source tumor data of a patient, including pathological image data, medical image data, genome and molecular data, and clinical and demographic indexes; secondly, processing the multi-source tumor data to form a unified data set; thirdly, aiming at different modal data, adopting a corresponding feature extraction sub-network to extract each modal depth feature; then, a cross-modal attention mechanism is adopted to realize feature dynamic weighting and deep fusion, and unified multi-modal fusion representation is obtained; then, constructing a prediction model, and outputting an immunotherapy benefited population classification identification result, RECIST curative effect multi-classification prediction and survival prediction; and finally, generating a visual result and a feature contribution degree ranking of a prediction basis, and forming a clinical auxiliary decision report. According to the method, the prediction accuracy and stability can be remarkably improved, and meanwhile, the method has result interpretability and clinical application value.

The invention relates to the technical field of immunotherapy, and provides a GPRC5D-targeted single-domain antibody, a chimeric antigen receptor and application of the GPRC5D-targeted single-domain antibody and the chimeric antigen receptor. Specifically, the invention provides a GPRC5D-targeted single-domain antibody, a GPRC5D-targeted chimeric antigen receptor (CAR) constructed by using the single-domain antibody, and an engineered immune effector cell containing the CAR. The invention also provides a single-domain antibody targeting GPRC5D, a chimeric antigen receptor and an application of the engineered immune effector cell containing the CAR in preparation of drugs for diagnosis, prevention and / or treatment of diseases or symptoms related to GPRC5D expression.

The invention belongs to the technical field of immunotherapy, and particularly relates to a method for improving NK cell functions by targeted inhibition of lactylation. The invention provides a method for improving functions of NK cells by targeted inhibition of lactylation, NK cell lactic acid transporters or modification enzymes in inhibition of the lactylation process are targeted, the modification enzymes are NK cell lactylation modification enzymes Writer or lactic acid coenzyme A synthetase, NK92MI lactylation modification is blocked, so that function depletion of the NK cells is reversed, and the NK cell function is improved. The function of the NK cell can be partially reversed by inhibiting the lactic acid modification, and the expression level of effector molecules of the NK92MI cell can be recovered.

The invention provides a novel platform for tumor immunotherapy. The platform is formed by self-assembly of full-heavy-chain human ferritin which can be jointly fused and expressed by a polypeptide prodrug mask which can be activated by protease and a mitochondrial disrupting peptide, and can specifically target a tumor microenvironment and induce ICD death of tumors. Meanwhile, an ion channel is formed in a protein shell of the platform, so that immunocompetence metal ions can be loaded in a cavity of the platform, and time-space synchronous anti-tumor immune activation can be carried out in cooperation with ICD. As the mitochondrial disrupting peptide and the metal ions can be optimized according to tumor types, the platform can be used for treating various tumors.

The invention discloses a covalent lysosome targeting chimera based on a nucleic acid aptamer and application of the covalent lysosome targeting chimera in protein degradation and immunotherapy, and belongs to the technical field of biology. The invention designs a covalent lysosome targeting chimera with click chemical reaction activity, and the simple and efficient covalent lysosome targeting chimera is used for realizing efficient protein degradation at the levels of cells and living bodies. When the tool is used for targeted degradation of immunotherapy biomarkers, immunogenic apoptosis of tumor cells can be caused, so that killing of an immune system to tumors is more efficiently activated. Meanwhile, the covalent lysosome targeting chimera overcomes the problem of immune-related side effects confronted by existing antibodies and polysaccharide peptide drugs, and can effectively avoid the potential occurrence risk of the immune-related side effects while efficiently degrading the target protein.

In some embodiments, a set of biomarkers is provided, selected from one or more of the group consisting of ITGB3, HTRA1, SERPINH1, TIMP3, ITGAV, COL11A1, ITGB7, CIITA, ZBP1, GZMA, IL18BP, and RNF213. The biomarker is used for predicting the response of a subject receiving immunotherapy to immunotherapy, has good performance in subjects suffering from different tumor types, has high universality, has the advantages of being low in cost, easy and convenient to use and the like, and has good application prospects. And the method is of great significance for predicting response to immunotherapy of cancers and personalized therapy.

The invention discloses a monoclonal antibody targeting all CD45 subtypes and application of the monoclonal antibody, and belongs to the field of monoclonal antibody preparation. The hybridoma cell strain capable of stably secreting all anti-human CD45 subtype antibodies is successfully obtained by stably expressing short and long molecular subtypes of human CD45 extracellular regions in L929 mouse fibroblasts, immunizing BALB / c mice with L929 cells expressing the two molecular subtypes of human CD45, and fusing splenocytes with SP20 myeloma cells after the serum titer reaches the standard. And the monoclonal antibody targeting all subtypes of CD45 is obtained. The monoclonal antibody provided by the invention shows a high-affinity binding characteristic with all human CD45 molecular subtypes, has important application value in the aspect of human CD45 molecular detection, and can be used as a therapeutic antibody in the fields of tumor immunotherapy, autoimmune disease treatment, transplant rejection resistance and the like.